What Do Retatrutide Clinical Trials Mean for You?

Key Takeaways

• Retatrutide achieved up to 28.3% average weight loss at the highest dose in TRIUMPH-1 trials, with 45.3% of participants losing 30% or more of body weight—comparable to bariatric surgery results.
• Retatrutide is not FDA-approved and only available through regulated clinical trials; buying it from unverified online sources poses serious health risks and should be avoided entirely.
• The drug's triple-receptor mechanism (GIP, GLP-1, glucagon) targets appetite, blood sugar, and fat burning simultaneously, showing superior weight loss compared to approved single or dual-target drugs like semaglutide and tirzepatide.
• Gastrointestinal side effects are common and dose-dependent, with nausea (42.4%), diarrhea (32%), and vomiting (25.3%) reported at the 12 mg dose, requiring close medical monitoring during treatment.

Weight loss medicine is changing fast. If you follow health news, you may have seen headlines about a new drug called retatrutide. Patients ask about it often during weight loss consultations. But what does the research actually show, and is it something you can get today?

This guide breaks down the retatrutide clinical trials in plain language. We will cover what the drug is, what the Phase 3 studies found, and what it means for your health journey right now. We will also explain why working with a trusted primary care team matters, even while this drug is still being tested.

What Is Retatrutide?

Retatrutide, also known as LY3437943, is an experimental medicine made by Eli Lilly. It is given as a once-weekly injection, similar to other weight loss drugs you may have heard of.

What makes retatrutide different is how it works. Most weight loss injections target one or two hormone receptors. Retatrutide targets three: GIP, GLP-1, and glucagon. Doctors call this a triple agonist. The idea is that hitting three targets at once may control appetite, blood sugar, and fat burning better than drugs that only hit one or two.

It is important to know this drug is not approved yet. The FDA has not cleared retatrutide for public use. You cannot get a prescription for it at a pharmacy today. It should only be used inside approved, closely monitored clinical trials.

Why Are the Retatrutide Clinical Trials Getting So Much Attention?

The buzz around retatrutide comes from its Phase 3 program, called TRIUMPH. This is a large set of trials testing the drug in adults with obesity, overweight, and related health problems like type 2 diabetes and heart disease.

Early results have been strong. But it is worth noting most of what we know so far comes from company press releases, not full published studies. Full peer-reviewed data will give doctors a more complete picture, including safety details that are not yet public.

TRIUMPH-1: The Core Weight Loss Trial

TRIUMPH-1 is the main trial testing retatrutide for weight loss in adults who are obese or overweight with at least one weight-related health issue. People with type 2 diabetes were not included in this particular study.

Here is what TRIUMPH-1 looked like:

• The trial enrolled 2,339 adults
• Participants received one of three doses: 4 mg, 9 mg, or 12 mg weekly, or a placebo
• The main treatment period lasted 80 weeks, about a year and a half
• Doses were slowly increased over time to help the body adjust

The weight loss numbers reported by Eli Lilly in May 2026 were notable. At 80 weeks, average weight loss was:

1. 19.0% with the 4 mg dose
2. 25.9% with the 9 mg dose
3. 28.3% with the 12 mg dose
4. Only 2.2% with placebo

At the highest dose, 45.3% of participants lost 30% or more of their body weight by week 80. That level of weight loss is close to what some people achieve with bariatric surgery, according to reporting from Tech Times.

An extension group from TRIUMPH-1 gave an even longer view. In this subgroup, 532 people with higher starting BMI stayed on treatment and moved up to their best-tolerated dose. By week 104, they averaged about 30.3% weight loss.

TRIUMPH-2: Weight Loss With Type 2 Diabetes

TRIUMPH-2 tested retatrutide in adults who have overweight or obesity along with type 2 diabetes. This group often has a harder time losing weight, so the results here matter a lot for primary care planning.

Reported results at 80 weeks showed:

• 12.7% average weight loss with the 4 mg dose
• 19.1% average weight loss with the 9 mg dose
• 20.8% average weight loss with the 12 mg dose
• Blood sugar control (measured by HbA1c) dropped by about 1.6 percentage points

This dual benefit, weight loss plus better blood sugar control, is exactly what many patients managing diabetes hope for in a single treatment.

What Side Effects Have Been Reported?

No weight loss drug works without some tradeoffs. The retatrutide clinical trials reported gastrointestinal side effects as the most common complaint, especially at higher doses.

At the 12 mg dose in TRIUMPH-1, reported side effects included:

These numbers are company-reported and need confirmation once full study results are published. Still, they give a useful early picture.

Dropout rates due to side effects also rose with higher doses. In TRIUMPH-1, discontinuation rates were:

1. 4.1% at the 4 mg dose
2. 6.9% at the 9 mg dose
3. 11.3% at the 12 mg dose
4. 4.9% with placebo

This pattern is common with GLP-1 style medications. Slow dose increases and close monitoring by a medical team help many patients manage these symptoms.

How Does Retatrutide Compare to Other Weight Loss Drugs?

Patients often ask how retatrutide stacks up against semaglutide or tirzepatide, two medicines already used for weight loss and diabetes care. Here is a simple comparison based on available trial data and drug mechanism:

Retatrutide's triple-target approach may explain the larger reported weight loss numbers. But because it is still in trials, we do not yet have the long-term safety data that approved drugs have collected over years of real-world use.

Who Can Join a Retatrutide Clinical Trial?

Clinical trials have strict entry rules to keep participants safe and to get clear results. General criteria across the TRIUMPH program have included:

• Adults with obesity or overweight plus at least one weight-related condition
• Specific BMI ranges set by each individual trial
• For some trials, a diagnosis of type 2 diabetes, knee osteoarthritis, or cardiovascular risk factors
• No major uncontrolled medical conditions that could interfere with the study

You can find official trial listings and eligibility details through resources like ClinicalTrials.gov. If you are curious whether a trial fits your situation, your primary care doctor can help you understand your options and risks before you sign up for anything.

What Should You Do While Retatrutide Is Still Being Tested?

Waiting for a new drug to gain approval can feel frustrating, especially if you have struggled with weight for years. The good news is that effective, medically supervised weight loss options already exist today.

Here are steps you can take right now:

1. Schedule a comprehensive wellness visit to review your current health status
2. Ask about approved weight loss programs that use proven medications and lifestyle coaching
3. Get a body composition analysis to track your progress with real data, not just a scale number
4. Discuss DNA gene testing to understand how your body responds to diet and exercise
5. Stay in touch with your care team so you are informed the moment new treatments become available

Do not buy retatrutide from unverified online sellers. Because it is not approved, any product sold outside a legitimate clinical trial has not been checked for safety or purity. This can put your health at serious risk.

Why Primary Care Matters More Than Ever

New weight loss drugs make headlines, but lasting health improvement starts with a solid primary care relationship. A good provider looks at your whole health picture, not just one number on a scale.

At InCare, our team combines proven medical treatment with modern tools like metabolic breath analysis and personalized weight loss plans. We serve patients across Tampa and Riverview, Florida, with a focus on prevention and whole-body health.

We also stay current on emerging research, including trials like TRIUMPH, so we can guide you toward safe, evidence-based choices. When retatrutide or similar drugs do receive approval, primary care teams will need to address dosing, side effect management, and coordination with specialists, exactly the kind of ongoing care InCare already provides for existing weight loss treatments.

If you want to see how other patients have experienced care at our clinics, you can visit us on Google — InCare to read real reviews from the Tampa and Riverview community. You can also follow our updates on Facebook, Instagram, and TikTok for health tips and clinic news.

The Bottom Line on Retatrutide Clinical Trials

Retatrutide shows real promise. The Phase 3 TRIUMPH trials reported weight loss numbers higher than many current treatments, along with meaningful blood sugar improvements for people with type 2 diabetes. But it remains an investigational drug. Full, peer-reviewed data is still needed before it can be prescribed outside of a clinical trial setting.

In the meantime, you do not have to wait to start improving your health. Proven weight loss programs, careful screening, and consistent primary care support can help you make real progress today.

Ready to talk about your weight loss goals with a team that understands the latest research? Book your appointment today and take the next step toward a healthier you. Or if you have questions first, feel free to reach out to our team and we will help you find the right path forward.

FAQs

Q: What is retatrutide and how does it work?

A: Retatrutide is an investigational once-weekly injectable medicine that acts on three hormone receptors: GIP, GLP-1, and glucagon. This triple-action approach is designed to affect appetite, blood sugar, and fat metabolism at the same time. It remains unapproved and is only available through regulated clinical trials.

Q: Is retatrutide FDA approved or available by prescription?

A: No, retatrutide is not approved by the FDA or any major regulator as of 2026. It cannot be legally prescribed or purchased outside of approved clinical trial programs, and patients should avoid unverified online sources claiming to sell it.

Q: How much weight loss was reported in retatrutide clinical trials?

A: In the TRIUMPH-1 trial, average weight loss at 80 weeks reached 28.3% at the highest 12 mg dose, compared to 2.2% with placebo. An extension group reached about 30.3% average weight loss by week 104, though these are company-reported figures awaiting full publication.

Q: What side effects have been reported with retatrutide?

A: The most common side effects reported were gastrointestinal, including nausea, diarrhea, constipation, and vomiting. These occurred more frequently at higher doses, and discontinuation rates due to side effects also increased with dose.

Q: How does retatrutide compare with semaglutide or tirzepatide?

A: Retatrutide targets three hormone receptors compared to one for semaglutide and two for tirzepatide, which may explain its higher reported weight loss percentages in trials. However, semaglutide and tirzepatide are already FDA-approved with established long-term safety records, while retatrutide is still investigational.

Our Service Area